LINC01830: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

Target Name: LINC01830

NCBI ID: G105374322

LINC01830

Other Name(s): long intergenic non-protein coding RNA 1830 | Uncharacterized LOC105374322 | LOC105374322

LINC01830: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

Introduction

LINC01830 is a long non-coding RNA (lncRNA) that has been identified in various genomes. It is characterized by its ability to be expressed in various cell types and its unique 3'-end structure, which consists of a 70-amino acid tail followed by a variable-length 5'-end. LINC01830 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Drug Target Potential

The drug targeting potential of LINC01830 is due to its unique structure and various biochemical properties. One of the key factors that make LINC01830 a potential drug target is its ability to interact with various protein partners. LINC01830 has been shown to interact with several protein partners, including the transcription factor, NF-kappa-B, and the protein kinase, p300.

Additionally, LINC01830 has been shown to play a role in various signaling pathways, including the NF-kappa pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development of various diseases, including cancer. Therefore, LINC01830 may be a potential drug target for therapies that target these processes.

Another potential mechanism by which LINC01830 may be targeted is its role in cell adhesion. LINC01830 has been shown to be involved in the formation of tight junctions, which are a type of cell-cell adhesion structure. tight junctions are critical for maintaining tissue structure and function, and are also involved in various diseases, including cancer. Therefore, LINC01830 may be a potential drug target for therapies that target cell adhesion.

Expression and Function

LINC01830 has been shown to be expressed in various cell types, including neurons, muscle cells, and cancer cells. It has also been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

In terms of its function, LINC01830 has been shown to be involved in the regulation of various gene expression. For example, LINC01830 has been shown to be involved in the regulation of the expression of the gene, PAX7. PAX7 is a transcription factor that is involved in the regulation of various cellular processes, including cell adhesion and differentiation.

In addition, LINC01830 has also been shown to be involved in the regulation of the expression of the gene, NF-kappa-B. NF-kappa-B is a protein that is involved in various cellular processes, including inflammation and stress response.

Conclusion

In conclusion, LINC01830 is a long non-coding RNA that has been identified in various genomes. It has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation. Its unique structure and various biochemical properties make LINC01830 a potential drug target. Additionally, LINC01830 has been shown to interact with several protein partners and play a role in various signaling pathways, including the NF-kappa pathway. Therefore, LINC01830 may be a valuable tool for the development of new therapies.

Protein Name: Long Intergenic Non-protein Coding RNA 1830

The "LINC01830 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01830 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets